What is AMPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.18B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AMPH?

P/E (TTM) is 13.61 and 52-week range is $16.65 to $29.52 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AMPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AMPH?

The company profile lists revenue (TTM) near $702M, net income (TTM) near $76M, EPS (TTM) near $1.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Amphastar Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rancho Cucamonga, California, US, 42.5M shares outstanding, ISIN US03209R1032 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Amphastar Pharmaceuticals, Inc.

$AMPH

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. The company is headquartered in Rancho Cucamonga, California and currently employs 1,976 full-time employees. The company went IPO on 2014-06-25. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The firm manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. The company manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. The company is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.

Employees

1,976

Website

amphastar.com/

IPO

2014-06-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US03209R1032

Headquarters

Rancho Cucamonga, California, US

Shares outstanding

42.5M

NAICS sector

Manufacturing

Institutional ownership

69.52%

Browse other companiesFree AI scores and summaries for more stocks